Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
VERUMIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update.
Veru to Report Fiscal Year 2025 Financial Results on December 17th
VERUMIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update.
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
VERU--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone--
--Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation--
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology
VERUNEW YORK--(BUSINESS WIRE)--Laxxon - Veru Announcement
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
VERUMIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic endpoints in a clinical study.
Veru Announced Topline Safety Results From Phase 2b QUALITY Study Of Enobosarm 3mg, Enobosarm 6mg, Or Placebo To Enhance Fat Loss And To Prevent Muscle Loss In Older Patients Receiving Semaglutide (Wegovy) For Chronic Weight Management
VERUVeru Q2 EPS $(0.05) Beats $(0.06) Estimate
VERUA Peek at Veru's Future Earnings
VERUVeru Q1 Adj EPS $(0.07) Beats $(0.08) Estimate
VERUVeru Q1 2025 GAAP EPS $(0.06) Beats $(0.07) Estimate, Cash, Cash Equivalents, And Restricted Cash Were $26.6M
VERUHC Wainwright & Co. Reiterates Buy on Veru, Maintains $3 Price Target
VERUVeru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek
VERUFDA Schedules Adcomm For Veru's Cancer Drug Repurposed For COVID-19
VERUVeru Option Alert: May 20 $7.5 Calls Sweep (17) near the Ask: 500 @ $2.099 vs 2883 OI; Earnings 5/12 Before Open Ref=$8.9199
VERUVeru Whale Trades Spotted
VERUA whale with a lot of money to spend has taken a noticeably bearish stance on Veru.
Looking at options history for Veru (NASDAQ:VERU) we detected 21 strange trades.
Veru Shares Move Lower; Culper Research Release Short Report On Stock
VERUFDA Grants Veru Pre-Emergency Use Authorization Meeting Date For Sabizabulin Phase 3 COVID-19 Study
VERUHow Is The Market Feeling About Veru Inc?
VERUVeru Inc's (NASDAQ:VERU) short percent of float has fallen 11.11% since its last report. The company recently reported that it has 2.89 million shares sold short, which is 4.48% of all regular shares that are available for trading.
